Percutaneous injection of chemotherapeutic drugs in the guidance of magnetic resonance imaging for the treatment of cholangiocarcinoma

Case Reports and Clinical Practice Review

Volumn 16, Issue 12, 2010, Pages

  Liu, Zhi Hua ^a   Zhang, Peng ^a   Zhou, Yun Kun ^a   Qin, Huan Long ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Cholangiocarcinoma; Magnetic resonance imaging; Percutaneous injection

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; OXALIPLATIN;

ARTICLE; BILE DUCT CARCINOMA; CANCER MORTALITY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOSTASIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INOPERABLE CANCER; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MORBIDITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; SURVIVAL TIME; BILE DUCT TUMOR; DRUG DELIVERY SYSTEM; HEPATIC DUCT; INTRADERMAL DRUG ADMINISTRATION; METHODOLOGY;

ADMINISTRATION, CUTANEOUS; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; CHOLANGIOCARCINOMA; DRUG DELIVERY SYSTEMS; HUMANS; MAGNETIC RESONANCE IMAGING;

EID: 79751489368     PISSN: 15076164     EISSN: 16433742     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. de Groen PC, Gores GJ, LaRusso NF et al: Biliary tract cancers. N Engl J Med, 1999; 341(18): 1368-78
2. Liu ZH, He YP, Qin H: The growth-inhibition effect of tamoxifen in the combination chemotherapeutics on the human cholangiocarcinoma cell line QBC939. Mol Biol Rep, 2009
3. Lazaridis KN, Gores GJ: Cholangiocarcinoma. Gastroenterology, 2005; 128(6): 1655-67
4. Aljiffry M, Walsh MJ, Molinari M: Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol, 2009; 15(34): 4240-62
5. Jarnagin WR, Fong Y, DeMatteo RP et al: Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg, 2001; 234(4): 507-17; discussion 17-19
6. Yamao T, Isomoto H, Yamaguchi N et al: Magnified endoscopic observation using narrow-band imaging of periampullary adenoma in a patient with familial adenomatous polyposis. Med Sci Monit, 2009; 15(12): CS169-73
7. Kornberg A, Kupper B, Thrum K et al: Recurrence-free long-term survival after liver transplantation in patients with 18F-FDG non-avid hilar cholangiocarcinoma on PET. Am J Transplant, 2009; 9(11): 2631-36
8. Heimbach J: Hilar cholangiocarcinoma and liver transplantation. Transplantation, 2009; 88(3): 299-300
9. Schwartz JJ, Hutson WR, Gayowski TJ, Sorensen JB: Liver transplantation for cholangiocarcinoma. Transplantation, 2009; 88(3): 295-98
10. Borie F, Niampa H, Bouvier AM et al: [Current management and prognosis of intrahepatic cholangiocarcinoma in France]. Gastroenterol Clin Biol, 2009; 33(10-11): 971-76
11. Laurent S, Monsaert E, Boterberg T et al: Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study. Ann Oncol, 2009; 20(8): 1369-74
12. Lindor KD, Kowdley KV, Luketic VA et al: High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology, 2009; 50(3): 808-14
13. Sirica AE: Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology, 2005; 41(1): 5-15
14. Ferguson PJ, Brisson AR, Koropatnick J, Vincent MD: Enhancement of cytotoxicity of natural product drugs against multidrug resistant variant cell lines of human head and neck squamous cell carcinoma and breast carcinoma by tesmilifene. Cancer Lett, 2009; 274(2): 279-89
15. Regimbeau JM, Fuks D, Chatelain D et al: [Surgical management of resectable hilar cholangiocarcinoma]. Gastroenterol Clin Biol, 2008; 32(6-7): 620-31
16. Coufal M, Invernizzi P, Gaudio E et al: Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma. Int J Cancer, 2010; 126(9): 2112-22
17. Rao S, Cunningham D, Hawkins RE et al: Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer, 2005; 92(9): 1650-54
18. Liu ZH, He YP, Zhou Y et al: Establishment and identification of the human multi-drug-resistant cholangiocarcinoma cell line QBC939/ADM. Mol Biol Rep, 2010
19. Szakacs G, Paterson JK, Ludwig JA et al: Targeting multidrug resistance in cancer. Nat Rev Drug Discov, 2006; 5(3): 219-34
20. Zhu W, Shan X, Wang T et al: miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer, 2010; 127(11): 2520-29
21. Matsuoka H, Yano K, Katsuta E et al: Advantages and safety of local treatment with MMC/Beriplast P for cancer tumors. Cancer Chemother Pharmacol, 1996; 38(6): 508-12
22. Pan H, Ma X, Li M et al: Ultrasound assistant chemotherapy may be a novel modality for solid tumors. Med Hypotheses, 2009; 73(4): 526-27
23. Issels RD: Hyperthermia adds to chemotherapy. Eur J Cancer, 2008; 44(17): 2546-54
24. Stahl R, Wang T, Lindner LH et al: Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS). Int J Hyperthermia, 2009; 25(4): 289-98
25. Yamada Y, Itoh Y, Aoki S et al: Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium. Cancer Chemother Pharmacol, 2009; 64(6): 1079-83
26. Demmy TL, Tomaszewski G, Dy GK et al: Thoracoscopic organ suffusion for regional lung chemotherapy (preliminary results). Ann Thorac Surg, 2009; 88(2): 385-90; discussion 90-91
27. Jarnagin WR, Schwartz LH, Gultekin DH et al: Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol, 2009; 20(9): 1589-95
28. Jin C, Yao L, Long J et al: Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma. Chin Med J (Engl), 2009; 122(3): 284-90
29. Xu J, Zhong Y, Weixin N et al: Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery. Ann Surg, 2007; 245(4): 583-90
30. Winch PD, Stevens W: Using a thoracic epidural catheter in a high-risk pediatric transplant patient. Ann Thorac Surg, 2009; 88(2): 654-56
31. Myrdal G, Lamberg K, Lambe M et al: Regional differences in treatment and outcome in non-small cell lung cancer: a population-based study (Sweden). Lung Cancer, 2009; 63(1): 16-22
32. Frech SA, Dupont HL, Bourgeois AL et al: Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet, 2008; 371(9629): 2019-25
33. Li JW, Feng B, Wu L et al: Intraoperative cholangiography in combination with laparoscopic ultrasonography for the detection of occult choledocholithiasis. Med Sci Monit, 2009; 15(9): MT126-30
34. Rimola J, Forner A, Reig M et al: Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology, 2009; 50(3): 791-98
35. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet, 2005; 366(9493): 1303-14
36. Labriola D, Livingston R: Possible interactions between dietary antioxidants and chemotherapy. Oncology-New York, 1999; 13(7): 1003-8
37. Conklin KA: Cancer chemotherapy and antioxidants. J Nutr, 2004; 134(11): 3201S-4S
38. Oettle H, Post S, Neuhaus P et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA, 2007; 297(3): 267-77
39. Ismail A, Ramsis R, Sherif A et al: Use of human amniotic stem cells for common bile duct reconstruction: vascularized support of a free amnion graft. Med Sci Monit, 2009; 15(9): BR243-47